The first patient in Centrexion Therapeutics Corp.'s Phase 3 VICTORY-1 clinical trial has been dosed with CNTX-4975, a synthetic trans-capsaicin injection for the treatment of chronic moderate to severe pain due to knee osteoarthritis.
Biologics
Bone Therapeutics finished patient recruitment for its Phase IIA lumbar spinal fusion study.
Houston-based regenerative medicine company SpinalCyte completed the first double-blind, placebo-controlled human trial using CybroCell, a human dermal fibroblast injection to treat degenerative disc disease.
Stempeutics Research signed an outlicensing deal with Alkem Laboratories for the knee osteoarthritis therapy Stempeucel, according to Business Today.
Bioventus extended its agreement with Seikagaku Corp. to continue distributing Supartz Fx. Under the terms of this agreement, Bioventus will be Supartz Fx's exclusive distributor in the U.S. through May 2028.
Advertisement
Osiris selected Jason Keefer to serve as interim president and CEO.
U.S. Stem Cell reported a 106 percent revenue increase for the third quarter of 2017, reflecting a surging demand for stem cell treatments at its clinics.
Orthobiologics company Royal Biologics introduced Amnio-Maxx.
Regenerative medicine company Orthocell successfully conducted a pre-clinical evaluation using CelGro collagen rope for ACL reconstruction.
Medical device company CartiHeal secured a $2.5 million investment from Bioventus, bringing the latest financing round to $21 million. The funding will go to CartiHeal's ongoing Agili-C IDE clinical study.